Literature DB >> 28289797

[Epidemiology and causes of Parkinson's disease].

C M Lill1, C Klein2.   

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease and has a growing socioeconomic impact due to demographic changes in the industrial nations. There are several forms of PD, a fraction of which (<5%) are monogenic, i. e. caused by mutations in single genes. At present, six genes have been established for the clinically classical form of parkinsonism including three autosomal dominantly (SNCA, LRRK2, VPS35) and three autosomal recessively inherited ones (Parkin, PINK1, DJ-1). In addition, there are a plethora of genes causing atypical forms of parkinsonism. In contrast, idiopathic PD is of a multifactorial nature. Genome-wide association studies have established a total of 26 genetic loci for this form of the disease; however, for most of these loci the underlying functional genetic variants have not yet been identified and the respective disease mechanisms remain unresolved. Furthermore, there are a number of environmental and life style factors that are associated with idiopathic PD. Exposure to pesticides and possibly a history of head trauma represent genuine risk factors. Other PD-associated factors, such as smoking and intake of coffee and alcohol may not represent risk factors per se and the cause-effect relationship has not yet been elucidated for most of these factors. A patient with a positive family history and/or an early age of disease onset should undergo counseling with respect to a possible monogenic form of the disease. Disease prediction based on genetic, environmental and life style factors is not yet possible for idiopathic PD and potential gene-specific therapies are currently in the development or early testing phase.

Entities:  

Keywords:  Environment; Life style; Mutation; Risk; SNP

Mesh:

Substances:

Year:  2017        PMID: 28289797     DOI: 10.1007/s00115-017-0288-0

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  50 in total

1.  Risk tables for parkinsonism and Parkinson's disease.

Authors:  Alexis Elbaz; James H Bower; Demetrius M Maraganore; Shannon K McDonnell; Brett J Peterson; J Eric Ahlskog; Daniel J Schaid; Walter A Rocca
Journal:  J Clin Epidemiol       Date:  2002-01       Impact factor: 6.437

Review 2.  Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.

Authors:  Michael A Schwarzschild; Kui Xu; Emin Oztas; Jacobus P Petzer; Kay Castagnoli; Neal Castagnoli; Jiang-Fan Chen
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

3.  Genetics meets environment: evaluating gene-environment interactions in neurologic diseases.

Authors:  Connie Marras; Samuel M Goldman
Journal:  Semin Neurol       Date:  2012-01-21       Impact factor: 3.420

4.  The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive Parkinsonism with generalized seizures.

Authors:  Catharine E Krebs; Siamak Karkheiran; James C Powell; Mian Cao; Vladimir Makarov; Hossein Darvish; Gilbert Di Paolo; Ruth H Walker; Gholam Ali Shahidi; Joseph D Buxbaum; Pietro De Camilli; Zhenyu Yue; Coro Paisán-Ruiz
Journal:  Hum Mutat       Date:  2013-07-19       Impact factor: 4.878

Review 5.  The epidemiology of Parkinson's disease: risk factors and prevention.

Authors:  Alberto Ascherio; Michael A Schwarzschild
Journal:  Lancet Neurol       Date:  2016-10-11       Impact factor: 44.182

6.  PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism.

Authors:  Christine Klein; Ana Djarmati; Katja Hedrich; Nora Schäfer; Cesa Scaglione; Roberta Marchese; Norman Kock; Birgitt Schüle; Anja Hiller; Thora Lohnau; Susen Winkler; Karin Wiegers; Robert Hering; Peter Bauer; Olaf Riess; Giovanni Abbruzzese; Paolo Martinelli; Peter P Pramstaller
Journal:  Eur J Hum Genet       Date:  2005-09       Impact factor: 4.246

7.  Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee.

Authors:  Taye H Hamza; Honglei Chen; Erin M Hill-Burns; Shannon L Rhodes; Jennifer Montimurro; Denise M Kay; Albert Tenesa; Victoria I Kusel; Patricia Sheehan; Muthukrishnan Eaaswarkhanth; Dora Yearout; Ali Samii; John W Roberts; Pinky Agarwal; Yvette Bordelon; Yikyung Park; Liyong Wang; Jianjun Gao; Jeffery M Vance; Kenneth S Kendler; Silviu-Alin Bacanu; William K Scott; Beate Ritz; John Nutt; Stewart A Factor; Cyrus P Zabetian; Haydeh Payami
Journal:  PLoS Genet       Date:  2011-08-18       Impact factor: 5.917

8.  Lack of replication of the GRIN2A-by-coffee interaction in Parkinson disease.

Authors:  Ismaïl Ahmed; Pei-Chen Lee; Christina M Lill; Susan Searles Nielsen; Fanny Artaud; Lisa G Gallagher; Marie-Anne Loriot; Claire Mulot; Magali Nacfer; Tian Liu; Joanna M Biernacka; Sebastian Armasu; Kari Anderson; Federico M Farin; Christina Funch Lassen; Johnni Hansen; Jørgen H Olsen; Lars Bertram; Demetrius M Maraganore; Harvey Checkoway; Beate Ritz; Alexis Elbaz
Journal:  PLoS Genet       Date:  2014-11-20       Impact factor: 5.917

Review 9.  Meta-analysis of early nonmotor features and risk factors for Parkinson disease.

Authors:  Alastair J Noyce; Jonathan P Bestwick; Laura Silveira-Moriyama; Christopher H Hawkes; Gavin Giovannoni; Andrew J Lees; Anette Schrag
Journal:  Ann Neurol       Date:  2012-10-15       Impact factor: 10.422

10.  A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease.

Authors:  E M Hill-Burns; N Singh; P Ganguly; T H Hamza; J Montimurro; D M Kay; D Yearout; P Sheehan; K Frodey; J A McLear; M B Feany; S D Hanes; W J Wolfgang; C P Zabetian; S A Factor; H Payami
Journal:  Pharmacogenomics J       Date:  2012-10-02       Impact factor: 3.550

View more
  7 in total

Review 1.  [The investigation of health outcomes in the German National Cohort: the most relevant endpoints and their assessment].

Authors:  Wolfgang Ahrens; Karin H Greiser; Jakob Linseisen; Tobias Pischon; Iris Pigeot
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-04       Impact factor: 1.513

Review 2.  Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke.

Authors:  Sejal Sharma; Saeideh Nozohouri; Bhuvaneshwar Vaidya; Thomas Abbruscato
Journal:  Life Sci       Date:  2021-03-11       Impact factor: 6.780

3.  Iron Concentration Does Not Differ in Blood but Tends to Decrease in Cerebrospinal Fluid in Parkinson's Disease.

Authors:  Xiaoli Shen; Huazhen Yang; Dongfeng Zhang; Hong Jiang
Journal:  Front Neurosci       Date:  2019-09-26       Impact factor: 4.677

4.  Improving Self-Awareness of Motor Symptoms in Patients With Parkinson's Disease by Using Mindfulness - A Study Protocol for a Randomized Controlled Trial.

Authors:  Timo Marcel Buchwitz; Franziska Maier; Andrea Greuel; Carsten Eggers
Journal:  Front Psychol       Date:  2020-04-17

5.  Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease.

Authors:  Marcus Pieterman; Scott Adams; Mandar Jog
Journal:  Front Neurol       Date:  2018-05-17       Impact factor: 4.003

6.  Deriving Implications for Care Delivery in Parkinson's Disease by Co-Diagnosing Caregivers as Invisible Patients.

Authors:  Franziska Thieken; Marlena van Munster
Journal:  Brain Sci       Date:  2021-12-10

Review 7.  The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson's Disease: A Systematic Literature Review of Pre-Clinical Studies.

Authors:  Samay Prakash; Wayne G Carter
Journal:  Brain Sci       Date:  2021-11-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.